Verseon (VSN) Share Price, News & Analysis

Company Overview

Verseon Corporation, a pharmaceutical company, designs and develops novel therapeutics for various diseases in the United States. The company is involved in developing oral anticoagulants for various cardiovascular indications with novel pharmacology; kallikrein inhibitors for the treatment of diabetic macular edema and hereditary angioedema; and novel angiogenesis inhibitors for the treatment of solid tumors. Verseon Corporation was founded in 2002 and is headquartered in Fremont, California.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 3,000 shs
• Average Volume: 75,334 shs
• Market Capitalization: £112.24 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: LON:VSN
• CIK: N/A
• Web: www.verseon.com
• Phone: +1-510-2259000
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 74.84
• Current Ratio: 3.36
• Quick Ratio: 3.09

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: 6.61
• Book Value: GBX 21 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 151,674,000
• Free Float: N/A
• Market Cap: £112.24 million
• Optionable: Not Optionable
• Beta: N/A